Project Grant R01AI189726
- Federal Grant Award Summary The University of California, San Diego received a $449,578 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of February 1, 2026, and completion date of January 31, 2031. This five-year award supports investigator-initiated biomedical research exploring the role of lytic polysaccharide monooxygenases (LPMOs) in the virulence and immunity...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $160,040 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective December 26, 2025, with a completion date of June 30, 2028. This Project Grant supports fundamental research investigating how the pathogenic bacterium Pseudomonas aeruginosa mechanically senses and responds to surface contact through cell envelope...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $720,035 Project Grant to the University of California, San Diego on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This five-year award, with a completion date of January 31, 2031, funds development and testing of a novel therapeutic delivery platform termed "living microrobot therapeutics" designed to treat severe...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $227,096 to University of California, Berkeley under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period July 1, 2025 through June 30, 2027. The award supports research utilizing Random Barcode Transposon Site Sequencing (RB-TNSEQ), an advanced genetic screening methodology, to identify nutrient acquisition strategies employed by...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $492,000 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 1, 2025, for a five-year project period concluding July 31, 2030. The award funds biochemical and structural characterization research of the elongasome and divisome protein complexes in Mycobacterium tuberculosis (MTB) and the...
- Federal Grant Award Summary Princeton University's Office of Research and Project Administration received a $451,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, with completion targeted for June 30, 2027. The research initiative employs chemical synthetic lethality methodology to identify novel antimicrobial targets in gram-negative bacterial...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California Santa Cruz a $430,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 2, 2026 through March 31, 2028. This award supports investigator-initiated research exploring the bacterial polyadenylase PAP I as a potential antimicrobial drug target. The project delivers scientific research services aimed at...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $192,672 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Leland Stanford Junior University, with a performance period from September 1, 2025, through August 31, 2030. This research initiative will investigate the role of PF bacteriophage in promoting Pseudomonas aeruginosa (PA) pathogenesis during chronic lung infections in individuals with...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1.79M Project Grant to The Leland Stanford Junior University under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2031. The Center for Phage Pharmaceuticals (Phage Pharm) will develop advanced research tools and pharmacologic approaches to optimize bacteriophage (phage) therapy for treating antimicrobial-resistant bacterial...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $395,692 Project Grant to the University of California, San Diego, effective July 17, 2025, through June 30, 2030, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research project, "Enhancing Bacteriophage Function with Coevolution and Synthetic Biology," addresses the critical public health challenge of antimicrobial resistance (AMR), which...
The California Institute of Technology received a $711,488 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The award supports fundamental research to elucidate maintenance metabolism in Pseudomonas aeruginosa, an opportunistic pathogen responsible for chronic infections in diabetic ulcers, cystic fibrosis, and other clinical contexts. The research leverages phenazine cycling—redox-active pigment production that enables energy conservation under anaerobic conditions—to understand how biofilm-forming bacteria maintain low metabolic activity while developing antibiotic tolerance, a critical knowledge gap that currently hinders treatment of chronic infections. The project employs a novel 96-well electrode system to conduct high-throughput studies of phenazine-mediated metabolism under anaerobic conditions, utilizing electrochemical measurements to quantify cellular metabolic rates in non-growing biofilm cells. This research is designed to generate scientific insights into bacterial physiology that may inform the development of therapeutic strategies to overcome antibiotic tolerance in chronic infections, thereby advancing public health outcomes for patients with difficult-to-treat bacterial infections.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $711.5k | 3/30/26 |